DC Field | Value | Language |
dc.contributor.author | Luca, Angela | - |
dc.contributor.author | Staver, Olga | - |
dc.date.accessioned | 2021-11-23T10:36:31Z | - |
dc.date.available | 2021-11-23T10:36:31Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | LUCA, Angela, STAVER, Olga. Combined otologic drugs on pharmaceutical market of Moldova. In: MedEspera: the 5th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2014, pp. 239-240. | en_US |
dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/18631 | - |
dc.description | Department of Pharmaceutical and
Toxicological Chemistry, State University of Medicine and Pharmacy "Nicolae Testemiţanu", Republic of Moldova | en_US |
dc.description.abstract | Introduction: About one-tenth of medicinal products present on the pharmaceutical market
are fixed-dose combinations. Fixed-dose combination products are becoming a popular treatment
option because of increased patient’s compliance and convenience, improved clinical effectiveness,
reduced cost for the patient and reduced side effects. Due to this range of advantages, combined
drugs can be used in otorhinolaryngology practice, especially in the pharmacotherapy of ear
diseases, because of the severe consequences otitis media produces (such as deafness due to keloid
scars of the tympanic membrane).
Materials and methods: For research, State Nomenclature of medicines from Republic of
Moldova was used (26.03.2014); patient information leaflets; quality standards of analytical
documents and therapeutic protocols in otorhinolaryngology (section "ear diseases").
Results: There are 642 combined drugs including: 531 combined drugs, 75 phytotherapeutic
combined drugs and 36 biological combined drugs registered in State Nomenclature of drugs from Republic of Moldova. From these, approved drugs in otorhinolaryngology are 87 combined drugs, 20
phytotherapeutic combined drugs and 1 biological combined drug, which represents 13,55%, 3,11% and
0,15% from the total number of registered fixed-dose combination products, respectively, 16,38%,
26,67% and 2,77% from the number of registered specific combined products.
There are 5 registered otological drugs which represents 0,78% from the total number of
registered fixed-dose combination products and respectively, 0,94% from the number of registered
specific combined products. From these: 40% represents anti-infectives, 20% represents analgesics
and anesthetics and 40% represents corticosteroids and anti-infectives in combination. So, there is
no specific anti-adhesive drug combination for the treatment of eardrum keloids.
Conclusions: In conclusion it is important to develop a new anti-adhesive composition for the
treatment of keloids of the tympanic membrane, containing raw vegetable materials. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Ministry of Health of the Republic of Moldova, State Medical and Pharmaceutical University Nicolae Testemitanu, Medical Students and Residents Association | en_US |
dc.relation.ispartof | MedEspera: The 5th International Medical Congress for Students and Young Doctors, May 14-17, 2014, Chisinau, Republic of Moldova | en_US |
dc.subject | fixed-dose combinations | en_US |
dc.subject | combined drugs | en_US |
dc.subject | anti-adhesive substances | en_US |
dc.subject | keloids | en_US |
dc.title | Combined otologic drugs on pharmaceutical market of Moldova | en_US |
dc.type | Other | en_US |
Appears in Collections: | MedEspera 2014
|